LongevityBeginners – research newsNew to longevity? LongevityBeginners explains popular supplements in plain English: what they are, what research shows and how strong the evidence is.https://longevitybeginners.com/enCreatine for 12 weeks: adults aged 45 to 65 gained lean mass in a small US trialhttps://longevitybeginners.com/news/creatine-12-week-trial-middle-aged-older-adults/https://longevitybeginners.com/news/creatine-12-week-trial-middle-aged-older-adults/In a 12-week trial of 64 adults aged 45-65, creatine (10 g daily) was linked to more lean mass and, with exercise and diet, a bigger drop in body fat.Sun, 01 Nov 2026 00:00:00 GMTcreatinemusclehealthy agingrandomized controlled trialJournal of the International Society of Sports NutritionFish oil and muscle: new review finds no clear benefit for healthy adultshttps://longevitybeginners.com/news/omega-3-fish-oil-muscle-strength-meta-analysis/https://longevitybeginners.com/news/omega-3-fish-oil-muscle-strength-meta-analysis/A meta-analysis of placebo-controlled trials found no clear effect of omega-3 on muscle mass or strength in healthy adults, with very low certainty.Sun, 01 Nov 2026 00:00:00 GMTomega-3fish oilmusclemeta-analysishealthy agingNutritionHarvard-led team identifies SRSF1 as a candidate 'youthful' gene factor, with lifespan signal in micehttps://longevitybeginners.com/news/srsf1-transcriptomic-reprogramming-mice/https://longevitybeginners.com/news/srsf1-transcriptomic-reprogramming-mice/A Nature Aging study looked for factors that shift aged cells to a younger gene profile. SRSF1 stood out, with lifespan signals in small mouse tests.Sun, 01 Nov 2026 00:00:00 GMTpartial reprogrammingSRSF1transcriptomic clockmouse studycellular agingNature AgingLarge NOPARK trial: nicotinamide riboside did not slow early Parkinson's diseasehttps://longevitybeginners.com/news/nicotinamide-riboside-parkinsons-nopark-trial/https://longevitybeginners.com/news/nicotinamide-riboside-parkinsons-nopark-trial/A 410-person phase 3 trial in JAMA found nicotinamide riboside raised blood NAD but did not improve outcomes in early Parkinson's disease.Sun, 01 Nov 2026 00:00:00 GMTNAD+nicotinamide ribosideNRParkinson's diseaserandomized controlled trialJAMALife Biosciences reports first human data for OSK gene therapy ER-100 in glaucoma: three participantshttps://longevitybeginners.com/news/life-biosciences-er-100-first-human-data/https://longevitybeginners.com/news/life-biosciences-er-100-first-human-data/Life Biosciences says its OSK therapy ER-100 was well tolerated in three glaucoma patients to Day 56. Interim, company-reported, uncontrolled data.Sun, 01 Nov 2026 00:00:00 GMTpartial reprogrammingOSKLife BiosciencesER-100glaucomaphase 1industry newsNMN for 24 weeks lifted blood NAD+ in older adults, but hearing and fitness tests did not improvehttps://longevitybeginners.com/news/nmn-24-week-trial-older-adults/https://longevitybeginners.com/news/nmn-24-week-trial-older-adults/A 24-week placebo-controlled trial in adults aged 65+ found 1,250 mg a day of NMN raised blood NAD+ but did not improve hearing or physical performance.Sun, 01 Nov 2026 00:00:00 GMTNMNNAD+randomized controlled trialolder adultsnpj AgingSmall Dutch trial links senolytic combination to liver biopsy improvements in fibrotic MASHhttps://longevitybeginners.com/news/senolytic-dasatinib-quercetin-liver-trial/https://longevitybeginners.com/news/senolytic-dasatinib-quercetin-liver-trial/A 31-person trial linked dasatinib plus quercetin to better liver biopsy scores in fibrotic MASH. Small and hypothesis-generating.Sun, 01 Nov 2026 00:00:00 GMTsenolyticsdasatinibquercetincellular senescenceMASHliverclinical trialSpermidine for 12 months: small brain-scan differences in older adults, but no link to memoryhttps://longevitybeginners.com/news/spermidine-12-month-brain-scan-smartage/https://longevitybeginners.com/news/spermidine-12-month-brain-scan-smartage/An MRI analysis of 75 older adults found small blood-flow differences in one brain region after 12 months of spermidine, with no link to memory.Sun, 01 Nov 2026 00:00:00 GMTspermidinebrain healthMRIrandomized controlled trialAging and DiseaseUrolithin A for four weeks did not improve blood-vessel function in adults with obesityhttps://longevitybeginners.com/news/urolithin-a-4-week-trial-obesity-blood-vessels/https://longevitybeginners.com/news/urolithin-a-4-week-trial-obesity-blood-vessels/A 50-person trial in adults with obesity found 1,000 mg a day of urolithin A for four weeks did not significantly improve blood-vessel function.Sun, 01 Nov 2026 00:00:00 GMTurolithin Amitochondriaobesityrandomized controlled trialJAMA Network Open